ESTRO 2024 - Abstract Book

S279

Brachytherapy - Gynaecology

ESTRO 2024

Conclusion:

Image-guided adaptive BT in LACC patients with LTI represents a challenge especially when vaginal disease persists because residual GTV after CRT is an important prognostic factor of local control. The two different BT techniques implemented in this cohort allowed for dose escalation and appropriate volume coverage. The use of interstitial needles was preferred when the thickness of the vaginal residue remained more than> 5mm.

Keywords: cervical cancer, vaginal involvement

2874

Digital Poster

Interstitial brachytherapy in carcinoma cervix: long term results, toxicity and patterns of failure

Vivek J Anand 1 , Paul Simon 2 , Sudesh Deshpande 2 , vinay Babu 2 , Suresh Naidu 2 , Ritika Harjani- Hinduja 2 , Manish Bhadane 2 , Kannan Venkatesan 2 1 P D Hinduja Hospital, Radiation Oncology, Mumbai, India. 2 P D Hinduja Hospital, Radiation Oncology, mumbai, India

Purpose/Objective:

Brachytherapy has been the back bone of local control in carcinoma cervix. Trans-perineal interstitial template guided brachytherapy (TPI-BT) has been established as a technique to deliver dose to parametrial extension of disease as a boost in order to conform radiation dose better and reduce the morbidity to the adjacent normal tissues

Material/Methods:

Retrospective study included 51 cervical cancer patients of stage IIB – IVA staged as per federation of international obstetrics and Gynaecology (FIGO), received external beam radiation therapy (EBRT) and concurrent cisplatin chemotherapy followed by TPI-BT under anaesthesia between 2009 -2023. EBRT dose ranged between 45- 54Gy in 23-28 fractions to the bilateral pelvic nodes & primary, 5 fractions per week. TPI-BT was performed using Syed Neblett template, radiation dose delivered was 20 to 24 Gy in 4 fractions, 2 fractions per day, 6 hours apart over two days. 6 patients were lost to follow up, 45 patients were evaluated at last follow up. Standardized planned dose constraints were ICRU points or D0.1cc bladder 80%, rectum 75% and urethra 90% of the HDR dose per fraction. Disease free survival(DFS), overall survival (OS) and cancer specific survival (CSS) were the primary endpoints. Genito urinary (GU) and gastro intestinal (GI) toxicities were graded according to RTOG and patterns of recurrence were secondary end points. Correlation of EQD2 dose to tumour control, rectal and bladder toxicity using ANOVA.

Results: